

PRIOR AUTHORIZATION CRITERIA

DRUG CLASS **NARCOLEPSY AGENTS**

BRAND NAME
(generic)

PROVIGIL
(modafinil)

Status: CVS Caremark Criteria

Type: Initial Prior Authorization with Quantity Limit

POLICY

FDA-APPROVED INDICATIONS

Provigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea, or shift work disorder.

Limitations of Use

In OSA, Provigil is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating and during treatment with Provigil for excessive sleepiness.

Compendial Uses/ Limited Treatment Option

Fatigue related to multiple sclerosis^{8,9}

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The patient has a diagnosis of narcolepsy AND the diagnosis is confirmed by sleep lab evaluation
- OR**
- The patient has a diagnosis of Shift Work Disorder (SWD)
- OR**
- The patient has a diagnosis of obstructive sleep apnea (OSA) AND the diagnosis is confirmed by polysomnography
- AND**
- The patient has been receiving treatment for the underlying airway obstruction (e.g., continuous positive airway pressure [CPAP]) for at least one month
- OR**
- The requested drug is being prescribed for multiple sclerosis-related fatigue

Quantity Limits Apply.

60 tablets/25 days* or 180 tablets/75 days*

*The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.

REFERENCES

1. Provigil [package insert]. North Wales, PA: Cephalon, Inc.; July 2019.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.; 2021; Accessed March 12, 2021.
3. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: <https://www.micromedexsolutions.com>. Accessed March 12, 2021.

4. Morgenthaler TJ, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. *Sleep* 2007; 30(12):1705-11.
5. American Academy of Sleep Medicine. *International Classification of Sleep Disorders: Diagnostic and Coding Manual*. 3rd edition. Westchester, IL: American Academy of Sleep Medicine; 2014.
6. Epstein LJ, Kristo D, Strollo PJ et al. Clinical Guidelines for the Evaluation, Management and Long-term Care of Obstructive Sleep Apnea in Adults. *J Clinical Sleep Medicine* 2009;5(3):263-276.
7. Czeisler, CA et al. Modafinil for excessive sleepiness associated with shift work sleep disorder. *New England Journal of Medicine*. 2005; 353; 476-486.
8. Brown JN, Howard CA, Kemp DW. Modafinil for the treatment of multiple sclerosis-related fatigue. *Ann Pharmacother*. 2010 Jun; 44(6):1098-103.
9. Zifko UA, Rupp M, Schwarz S, et al. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. *J Neurol*. 2002; 249:983-987.